Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.44 USD | +0.14% | +4.26% | -32.90% |
Feb. 22 | Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says | MT |
Feb. 22 | Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating | MT |
Financials (USD)
Sales 2024 * | 441M | Sales 2025 * | 469M | Capitalization | 526M |
---|---|---|---|---|---|
Net income 2024 * | -95M | Net income 2025 * | -81M | EV / Sales 2024 * | 0.91 x |
Net cash position 2024 * | 125M | Net cash position 2025 * | 97.38M | EV / Sales 2025 * | 0.91 x |
P/E ratio 2024 * |
-5.47
x | P/E ratio 2025 * |
-6.58
x | Employees | 1,215 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Nevro Corp.
1 day | +0.14% | ||
1 week | +4.26% | ||
Current month | -0.82% | ||
1 month | -2.56% | ||
3 months | -34.63% | ||
6 months | -26.55% | ||
Current year | -32.90% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Thornal
CEO | Chief Executive Officer | 50 | 23-04-23 |
D. Grossman
CHM | Chairman | 63 | 19-03-18 |
Roderick MacLeod
DFI | Director of Finance/CFO | 57 | 20-06-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael DeMane
BRD | Director/Board Member | 67 | 11-03-16 |
Karen Prange
BRD | Director/Board Member | 60 | 19-12-16 |
D. Grossman
CHM | Chairman | 63 | 19-03-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 464 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 14.44 | +0.14% | 332,032 |
24-03-27 | 14.42 | +6.26% | 290,896 |
24-03-26 | 13.57 | -0.73% | 269,696 |
24-03-25 | 13.67 | +0.81% | 398,448 |
24-03-22 | 13.56 | -2.09% | 259,497 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.90% | 525M | |
+3.26% | 197B | |
+5.79% | 115B | |
+1.48% | 71.22B | |
+11.77% | 53.77B | |
+18.31% | 48.75B | |
+6.47% | 44.22B | |
+12.38% | 28.85B | |
+9.76% | 28.57B | |
+10.35% | 27.62B |